









Markets
/
Stocks
/
nasdaq-phat
/

Phathom Pharmaceuticals Inc

PHAT

10.580USD

0.0000.00%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

273.85MMarket Cap

LossP/E TTM



Phathom Pharmaceuticals Inc

10.580

0.0000.00%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Phathom Pharmaceuticals Inc

Currency: USD Updated: 2026-03-27

Key Insights

Phathom Pharmaceuticals Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 55 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 23.50.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Phathom Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

55 / 157

Overall Ranking

145 / 4542

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Phathom Pharmaceuticals Inc Highlights

StrengthsRisks

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s product candidates include VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker, or potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 25575.95% year-on-year.

Undervalued

The company’s latest PE is -3.49, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 60.04M shares, decreasing 29.64% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 4.14K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.09.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

23.700

Target Price

+119.65%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Phathom Pharmaceuticals Inc is 8.09, ranking 75 out of 157 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 57.58M, representing a year-over-year increase of 94.12%, while its net profit experienced a year-over-year increase of 71.59%.

Score

Industry at a Glance

Previous score

8.09

Change



Financials

6.24

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.22

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.49

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.53

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Phathom Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Phathom Pharmaceuticals Inc is 6.25, ranking 127 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is -3.49, which is -87.33% below the recent high of -0.44 and -38.08% above the recent low of -4.81.

Score

Industry at a Glance

Previous score

6.25

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 55/157

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Phathom Pharmaceuticals Inc is 8.36, ranking 39 out of 157 in the Pharmaceuticals industry. The average price target is 20.00, with a high of 29.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

8.36

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

23.700

Target Price

+119.65%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Phathom Pharmaceuticals Inc

PHAT

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Phathom Pharmaceuticals Inc is 6.80, ranking 60 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 11.94 and the support level at 9.61, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.90

Change

-0.1

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.147

Neutral

RSI(14)

42.905

Neutral

STOCH(KDJ)(9,3,3)

31.688

Neutral

ATR(14)

0.729

Low Volatility

CCI(14)

16.950

Neutral

Williams %R

69.474

Sell

TRIX(12,20)

-0.598

Sell

StochRSI(14)

78.325

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

10.494

Buy

MA10

10.708

Sell

MA20

10.801

Sell

MA50

12.140

Sell

MA100

13.685

Sell

MA200

12.266

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Phathom Pharmaceuticals Inc is 7.00, ranking 42 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 77.11%, representing a quarter-over-quarter decrease of 9.48%. The largest institutional shareholder is The Vanguard, holding a total of 3.17M shares, representing 4.02% of shares outstanding, with 1.29% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Frazier Life Sciences Management, L.P.

12.19M

-2.21%

Medicxi Ventures (UK) LLP

7.46M

Millennium Management LLC

5.08M

+22.14%

Abingworth Management Limited

3.50M

Invesco Advisers, Inc.

3.23M

-0.40%

The Vanguard Group, Inc.

Star Investors

3.22M

+15.36%

BlackRock Institutional Trust Company, N.A.

3.06M

+2.09%

Ensign Peak Advisors, Inc.

2.50M

-0.66%

New Enterprise Associates (NEA)

1.96M

683 Capital Management LLC

1.82M

-13.52%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Phathom Pharmaceuticals Inc is 5.47, ranking 65 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.62. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.